

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Izotropic Corporation** (the "Issuer").

Trading Symbol: **IZO**

Number of Outstanding Listed Securities: **22,499,999**

Date: **June 6, 2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On May 31, 2018, the Issuer completed its initial public offering (the "IPO") of 2,000,000 common shares in the capital of the Issuer (each, a "Share") at a price of \$0.10 per Share for gross proceeds of \$200,000.

Chippingham Financial Group Limited acted as agent (the "Agent") for the IPO. The Company paid the Agent a cash commission of \$20,000 and granted an aggregate of 200,000 agent's options, each of which entitles the holder thereof to purchase one Share at a price of \$0.10 per Share for a period of 24 months from the date of the listing of the Shares on the Canadian Securities Exchange (the "Exchange").

The Shares were approved for listing on the Exchange on May 31, 2018 and commenced trading on the Exchange on June 4, 2018 under the symbol IZO.

On May 31, 2018, the Issuer posted a listing statement dated May 31, 2018 (the "Listing Statement") in connection with the IPO. For further particulars of the IPO see the Listing Statement.

2. Provide a general overview and discussion of the activities of management.

During the month ended May 31, 2018, management worked towards completing the IPO.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Company is engaged in the development and commercialization of the "Isotropic Breast Imaging System" for application in proprietary diagnostic products for breast cancer to address the demand by the breast imaging medical community for a cost-effective, true 3-D breast imaging technology that improves patient comfort and delivers high diagnostic accuracy. The Company does not currently generate revenue. The technology is supported by two existing patents and five pending patents, which comprise the Licensed Patent Rights. For a detailed discussion of the business of the Issuer, refer to Section 4 – Narrative Description of Business in the Listing Statement.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See response to Item 1 above and the Listing Statement for further particulars.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

See response to Item 3 above and the Listing Statement for further particulars.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	2,000,000	See note 2 below	\$200,000 ⁽⁴⁾
Warrants to Purchase Shares	200,000	See note 3 below	Not applicable ⁽³⁾

(1) State aggregate proceeds and intended allocation of proceeds.

(2) Issued pursuant to the IPO. See response to Item 1 above.

(3) Granted to the Agent pursuant to the IPO. See response to Item 1 above.

(4) The Company intends to spend the proceeds of the IPO as stated in the Filing Statement. There may be circumstances, however, where, for sound business reasons, a reallocation of funds may be necessary.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **June 6, 2018**_____.

Robert Thast_____

Name of Director or Senior Officer

/s/ Robert Thast_____

Signature

Chief Executive Officer_____

Official Capacity

Issuer Details Name of Issuer Izotropic Corporation	For Month End May 2018	Date of Report YY/MM/D 18/06/06
Issuer Address 15718 39A Avenue, Surrey, BC V3Z 0L1		
City/Province/Postal Code Surrey, British Columbia, V6E 3T5	Issuer Fax No. Not Applicable	Issuer Telephone No. 604-542-9458
Contact Name Robert Thast	Contact Position Director and Chief Executive Officer	Contact Telephone No. 604-542-9458
Contact Email Address BThast@telus.net	Web Site Address Not Applicable	